Page 28 - Lupin

Lupin gets tentative USFDA nod for generic anti-depressant

Company's shares were trading at Rs 1,524.70, up 0.14% in the afternoon trade on BSE

Lupin arm gets USFDA nod to market generic Zyvox tablets

According to IMS MAT June sales data, Zyvox tablets had US sales of $273.6 million

Lupin gets CDSCO nod for indigestion treatment tablets

Acotiamide is approved for the treatment of post meal fullness, bloating and early satiety in functional dyspepsia by the CDSCO

Lupin gets USFDA nod for generic potassium deficiency drug

Company's subsidiary Gavis Pharmaceuticals has received final approval from USFDA to market potassium chloride extended release capsules

Lupin looks to launch 25 products in US this fiscal

Company expects to go ahead with launches on the dermatology front this year

Lupin Pharmaceuticals: Strong show fails to impress

Lukewarm domestic sales partly offset robust growth in US business; Ebitda short of estimates

Lupin Q1 profit up 55% on the back of overseas business

Net income from operations jumped 40% to Rs 4,439 cr

Lower tax rate boosts Lupin's Q1 net by 68%

Shares in Lupin fell as much as 6% to a one-month low of 1,598 rupees following the results, before closing down 5%

Lupin dips on weak Q1 operating margin

The stock dipped 5% to Rs 1,607, falling 7% from intra-day high of Rs 1,730 on the BSE.

Lupin expands Japan business with Rs 1,000 crore buy

Japan accounts for about 10% of Lupin's revenue and is its third biggest market after the US and India

Lupin to buy 21 products of Japan's Shionogi for Rs 1,000 crore

With 21 new brands, Kyowa will rank sixth amongst generic companies in the country

Competition Commission slaps Rs 73 cr fine on Lupin

CCI's order has come on a complaint filed by Maruti & Company

Lupin launches generic oral contraceptive tablets in US

Shares of Lupin closed at Rs 1,713.60 per scrip on BSE, up 1.37%

USFDA clears Lupin's Goa plant, closes July 2015 inspection

The Goa plant accounts for 50% of Lupin's US sales and adverse observations from FDA resulted in delayed product approvals for the company

Lupin surges on receiving EIR from USFDA for Goa facility

The stock moved higher by 9% to Rs 1,698 on the NSE.

Lupin records sharpest single day gain in three months

The stock ended higher by 4.4% to Rs 1,543 on the BSE, recorded its sharpest single day gain since March 30, 2016.

Lupin gets USFDA nod for fungal infection drug

Mumbai based Lupin produces and develops a wide range of branded & generic formulations, biotechnology products and APIs globally

Lupin shares fall 2% on product recall in US

Company's US arm Lupin Pharmaceuticals Inc is initiating the recall

Lupin recalls over 54,000 vials of anti-bacterial injection in US

Anti-bacterial injection Ceftriaxone are being recalled due to violation of current good manufacturing norms

Lupin gets final USFDA nod for fungal treatment drug

Lupin further said that the company shall commence promoting the products in the US shortly